Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENACT trial of adjunctive ENX-101 for focal seizures
NL-OMON59640Phase 2Withdrawn
- Sponsor
- Engrail Therapeutics
- Start
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Focal Onset Epilepsy comparing ENX-101 adjunctive therapy with Placebo adjunctive therapy (2 arms). Primary endpoint: Responder rate. Planned start Oct 2022; status: withdrawn.
02
Drugs
ENX-101
03
Conditions
Focal Onset Epilepsy
Beyond the preview
Go deeper on NL-OMON59640.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59640.